might interest some....Bristol Myers beats estimates with new drug sales surge
Bristol Myers Squibb ($BMY) outperformed in Q4 with adjusted earnings per share of $1.70 (compared to the expected $1.53) and revenue of $11.48B (surpassing the expected $11.19B). The sales boost was driven by higher sales of new drugs, including Reblozyl and Opdualag, contributing $1.07B, up 66% from the previous year.
fwiw...Opdualag had sales of $190M for 4th qtr of 2023, contrast this with sales of $45M for 3rd qtr 2022..
Media, page-617
-
- There are more pages in this discussion • 127 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $465.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.0¢ | 31.5¢ | $547.1K | 1.721M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 72820 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 49499 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |